Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products primarily in the United States, Europe, and South Korea. It offers Contrave for the treatment of obesity. The company also offers Contrave under the Mysimba brand name. Orexigen Therapeutics, Inc. was founded in 2002 and is headquartered in La Jolla, California. On March 12, 2018, Orexigen Therapeutics, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:OREX
CUSIP68616410
Phone858-875-8600
Debt
Debt-to-Equity Ratio-2.75
Current Ratio2.00
Quick Ratio1.71
Price-To-Earnings
Trailing P/E Ratio-0.03
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$33.71 million
Price / Sales0.12
Cash FlowN/A
Price / CashN/A
Book Value$3.91 per share
Price / Book0.06
Profitability
EPS (Most Recent Fiscal Year)($6.92)
Net Income$-24,520,000.00
Net Margins-192.65%
Return on EquityN/A
Return on Assets-68.53%
Miscellaneous
Employees132
Outstanding Shares18,890,000
Market Cap$4.21 million
Orexigen Therapeutics (NASDAQ:OREX) Frequently Asked Questions
What is Orexigen Therapeutics' stock symbol?
Orexigen Therapeutics trades on the NASDAQ under the ticker symbol "OREX."
How were Orexigen Therapeutics' earnings last quarter?
Orexigen Therapeutics, Inc. (NASDAQ:OREX) announced its quarterly earnings data on Monday, November, 13th. The biopharmaceutical company reported ($1.35) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($2.13) by $0.78. The biopharmaceutical company had revenue of $18.90 million for the quarter, compared to analyst estimates of $24.20 million. The company's quarterly revenue was up 170.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.12 EPS. View Orexigen Therapeutics' Earnings History.
What price target have analysts set for OREX?
1 analysts have issued 1 year price objectives for Orexigen Therapeutics' stock. Their forecasts range from $0.02 to $0.02. On average, they expect Orexigen Therapeutics' share price to reach $0.02 in the next twelve months. This suggests that the stock has a possible downside of 91.0%. View Analyst Price Targets for Orexigen Therapeutics.
What is the consensus analysts' recommendation for Orexigen Therapeutics?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Orexigen Therapeutics in the last year. There are currently 1 sell rating for the stock, resulting in a consensus recommendation of "Sell." View Analyst Ratings for Orexigen Therapeutics.
Who are some of Orexigen Therapeutics' key competitors?
Some companies that are related to Orexigen Therapeutics include Regulus Therapeutics (RGLS), THERAPIX BIOSCI/S (TRPX), Pulmatrix (PULM), Midatech Pharma (MTP), MusclePharm (MSLP), Amarillo Biosciences (AMAR), Endonovo Therapeutics (ENDV), DelMar Pharmaceuticals (DMPI), Adial Pharmaceuticals (ADIL), Uluru (ULUR), Kazia Therapeutics (KZIA), OHR Pharmaceutical (OHRP), Relmada Therapeutics (RLMD), Propanc Biopharma (PPCB) and Vital Therapies (VTL).
Who are Orexigen Therapeutics' key executives?
Orexigen Therapeutics' management team includes the folowing people:
- Mr. Michael A. Narachi, Pres, Chief Exec. Officer & Director (Age 59)
- Dr. Thomas R. Cannell D.V.M., Exec. VP, COO & Pres of Global Commercial Products (Age 56)
- Mr. Thomas P. Lynch, Exec. VP, Gen. Counsel, Chief Admin. Officer & Sec. (Age 51)
- Ms. Monica Forbes, VP & Acting CFO (Age 42)
- Mr. Stephen A. Moglia, Chief Accounting Officer, VP and Controller (Age 53)
How do I buy shares of Orexigen Therapeutics?
Shares of OREX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Orexigen Therapeutics' stock price today?
One share of OREX stock can currently be purchased for approximately $0.2229.
How big of a company is Orexigen Therapeutics?
Orexigen Therapeutics has a market capitalization of $4.21 million and generates $33.71 million in revenue each year. The biopharmaceutical company earns $-24,520,000.00 in net income (profit) each year or ($6.92) on an earnings per share basis. Orexigen Therapeutics employs 132 workers across the globe.
What is Orexigen Therapeutics' official website?
How can I contact Orexigen Therapeutics?
Orexigen Therapeutics' mailing address is 3344 N. TORREY PINES CT. SUITE 200, LA JOLLA CA, 92037. The biopharmaceutical company can be reached via phone at 858-875-8600 or via email at [email protected]
MarketBeat Community Rating for Orexigen Therapeutics (NASDAQ OREX)
MarketBeat's community ratings are surveys of what our community members think about Orexigen Therapeutics and other stocks. Vote "Outperform" if you believe OREX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OREX will underperform the S&P 500 over the long term. You may vote once every thirty days.
